244 related articles for article (PubMed ID: 30190344)
1. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Naik J; Themeli M; de Jong-Korlaar R; Ruiter RWJ; Poddighe PJ; Yuan H; de Bruijn JD; Ossenkoppele GJ; Zweegman S; Smit L; Mutis T; Martens ACM; van de Donk NWCJ; Groen RWJ
Haematologica; 2019 Mar; 104(3):e100-e103. PubMed ID: 30190344
[No Abstract] [Full Text] [Related]
2. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
Bride KL; Vincent TL; Im SY; Aplenc R; Barrett DM; Carroll WL; Carson R; Dai Y; Devidas M; Dunsmore KP; Fuller T; Glisovic-Aplenc T; Horton TM; Hunger SP; Loh ML; Maude SL; Raetz EA; Winter SS; Grupp SA; Hermiston ML; Wood BL; Teachey DT
Blood; 2018 Mar; 131(9):995-999. PubMed ID: 29305553
[TBL] [Abstract][Full Text] [Related]
3. Frequent, high density expression of surface CD38 as a potential therapeutic target in adult T-lineage acute lymphoblastic leukemia.
Koslowski S; Glauben R; Habringer S; Burmeister T; Keller U; Brüggemann M; Gökbuget N; Schwartz S
Haematologica; 2024 Feb; 109(2):661-665. PubMed ID: 37675513
[No Abstract] [Full Text] [Related]
4. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells.
Herrmann H; Kneidinger M; Cerny-Reiterer S; Rülicke T; Willmann M; Gleixner KV; Blatt K; Hörmann G; Peter B; Samorapoompichit P; Pickl W; Bharate GY; Mayerhofer M; Sperr WR; Maeda H; Valent P
Curr Cancer Drug Targets; 2012 Jan; 12(1):51-63. PubMed ID: 22165967
[TBL] [Abstract][Full Text] [Related]
5. Myeloid/NK cell acute leukemia with unique blast morphology: de novo or secondary leukemia?
Imashuku S; Kudo N; Sungkyu P; Shinbo M; Furukawa T; Iwae S
Int J Hematol; 2013 Oct; 98(4):509-11. PubMed ID: 24046180
[No Abstract] [Full Text] [Related]
6. [Acute lymphoblastic leukemia with T + PH1 monocytosis: a case report].
Braham Jmili N; Sendi H; Khelif A
Ann Biol Clin (Paris); 2011; 69(4):473-5. PubMed ID: 21896415
[TBL] [Abstract][Full Text] [Related]
7. Drugging DNA repair to target T-ALL cells.
Dasgupta Y; Golovine K; Nieborowska-Skorska M; Luo L; Matlawska-Wasowska K; Mullighan CG; Skorski T
Leuk Lymphoma; 2018 Jul; 59(7):1746-1749. PubMed ID: 29115896
[No Abstract] [Full Text] [Related]
8. [Successful treatment with clarithromycin for Mixed phenotype acute leukemia, T/myeloid, NOS].
Ohe M; Hashino S
Rinsho Ketsueki; 2010 Apr; 51(4):297-9. PubMed ID: 20467229
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid induction of CD38 antigen expression on normal and leukemic human myeloid cells: relationship with cell differentiation.
Prus E; Fibach E
Leuk Lymphoma; 2003 Apr; 44(4):691-8. PubMed ID: 12769347
[TBL] [Abstract][Full Text] [Related]
10. Insights on Metabolic Reprogramming and Its Therapeutic Potential in Acute Leukemia.
Di Martino L; Tosello V; Peroni E; Piovan E
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445444
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory effects of CD38-targeting antibodies.
van de Donk NWCJ
Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
[TBL] [Abstract][Full Text] [Related]
12. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia.
Hoehn D; Medeiros LJ; Chen SS; Tian T; Jorgensen JL; Ahmed Y; Lin P
Am J Clin Pathol; 2012 Feb; 137(2):213-9. PubMed ID: 22261446
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of Notch inhibition in T-cell acute lymphoblastic leukemia: rationale, caveats and promises.
Sarmento LM; Barata JT
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1403-15. PubMed ID: 21929314
[TBL] [Abstract][Full Text] [Related]
14. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia.
Keyhani A; Huh YO; Jendiroba D; Pagliaro L; Cortez J; Pierce S; Pearlman M; Estey E; Kantarjian H; Freireich EJ
Leuk Res; 2000 Feb; 24(2):153-9. PubMed ID: 10654451
[TBL] [Abstract][Full Text] [Related]
15. IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
Gianfelici V; Messina M; Paoloni F; Peragine N; Lauretti A; Fedullo AL; Di Giacomo F; Vignetti M; Vitale A; Guarini A; Chiaretti S; Foà R
Leuk Lymphoma; 2019 Mar; 60(3):829-832. PubMed ID: 30188230
[No Abstract] [Full Text] [Related]
16. Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity.
Hu X; Xu J; Sun A; Shen Y; He G; Guo F
Leuk Lymphoma; 2011 Dec; 52(12):2393-5. PubMed ID: 21745166
[No Abstract] [Full Text] [Related]
17. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
18. Targeting steroid resistance in T-cell acute lymphoblastic leukemia.
De Smedt R; Morscio J; Goossens S; Van Vlierberghe P
Blood Rev; 2019 Nov; 38():100591. PubMed ID: 31353059
[TBL] [Abstract][Full Text] [Related]
19. Importance of Acute Lymphoblastic Leukemia-type Therapy for Bilineal Acute Leukemia.
Nakagawa S; Okamoto Y; Kodama Y; Nishikawa T; Tanabe T; Kawano Y
J Pediatr Hematol Oncol; 2019 Aug; 41(6):504-506. PubMed ID: 30198961
[TBL] [Abstract][Full Text] [Related]
20. CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy.
Bras AE; Beishuizen A; Langerak AW; Jongen-Lavrencic M; Te Marvelde JG; van den Heuvel-Eibrink MM; Zwaan CM; van Dongen JJM; van der Velden VHJ
Br J Haematol; 2018 Jan; 180(2):292-296. PubMed ID: 27604396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
